Vnitr Lek 2021, 67(5):284-290 | DOI: 10.36290/vnl.2021.075

Osteoporosis in premenopausal women

Juraj Payer, Juraj Smaha, Martin Kužma, Zdenko Killinger, Peter Jackuliak
V. interná klinika Lekárskej fakulty UK a Univerzitnej nemocnice Bratislava

In contrast to postmenopausal women diagnostic process and treatment of premenopausal osteoporosis in young women reamin poorly defined. A low bone mineral density in premenopausal women is not associated with the same risk of fractures as in postmenopausal women, therefore diagnosis requires not only densitometric examination but depends on the consideration of other risk factors. Most cases of premenopausal osteoporosis are associated with chronic diseases affecting bone metabolism. Treatment of the underlying disease may improve bone density as well as bone quality. Rarely, a bone-specific antiporotic therapy may be used, although quality evidence is scarce. This article will review current opinion on definition, diagnosis and treatment of premenopausal osteoporosis.

Keywords: densitometry, treatment, premenopausal osteoporosis, risk of fracture.

Published: August 25, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Payer J, Smaha J, Kužma M, Killinger Z, Jackuliak P. Osteoporosis in premenopausal women. Vnitr Lek. 2021;67(5):284-290. doi: 10.36290/vnl.2021.075.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kanis JA et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 2020; 31(1): p. 1-12. Go to original source... Go to PubMed...
    2. Rozenberg S et al. How to manage osteoporosis before the age of 50. Maturitas, 2020; 138: p. 14-25. Go to original source... Go to PubMed...
    3. Khan AA, Syed Z. Bone densitometry in premenopausal women: synthesis and review. J Clin Densitom, 2004; 7(1): p. 85-92. Go to original source... Go to PubMed...
    4. Liu JM et al. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab, 2008; 26(2): p. 159-164. Go to original source... Go to PubMed...
    5. Cramarossa G. et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus, 2017; 26(4): p. 365-372. Go to original source... Go to PubMed...
    6. Sharma M, et al. Lean Mass and Disease Activity are the Best Predictors of Bone Mineral Loss in the Premenopausal Women with Rheumatoid Arthritis. Indian J Endocrinol Metab, 2018; 22(2): p. 236-243. Go to original source... Go to PubMed...
    7. Rahaman SH et al. Bone Health in Patients with Cushing's Syndrome. Indian J Endocrinol Metab, 2018; 22(6): p. 766-769. Go to original source... Go to PubMed...
    8. Dutta D et al. Occurrence & predictors of osteoporosis & impact of body composition alterations on bone mineral health in asymptomatic pre-menopausal women with HIV infection. The Indian journal of medical research, 2018; 147(5): p. 484-495. Go to original source... Go to PubMed...
    9. Cairoli E et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int, 2019. 30(6): p. 1255-1263. Go to original source... Go to PubMed...
    10. Martínez-Morillo MD. Grados, and S. Holgado, Premenopausal Osteoporosis: How to Treat? Reumatología Clínica (English Edition), 2012; 8(2): p. 93-97. Go to original source...
    11. Weaver CM et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int, 2016; 27(4): p. 1281-1386. Go to original source... Go to PubMed...
    12. Schousboe JT et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom, 2013; 16(4): p. 455-466. Go to original source... Go to PubMed...
    13. Shepherd JA et al. Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD. J Clin Densitom, 2015; 18(3): p. 274-286. Go to original source... Go to PubMed...
    14. Greendale GA et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). J Bone Miner Res, 2012; 27(1): p. 111-118. Go to original source... Go to PubMed...
    15. Ferrari S et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int, 2012; 23(12): p. 2735-2748. Go to original source... Go to PubMed...
    16. Lewiecki EM et al. Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases. Journal of Clinical Densitometry, 2017; 20(2): p. 134-152. Go to original source... Go to PubMed...
    17. Lewiecki EM et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone, 2008; 43(6): p. 1115-1121. Go to original source... Go to PubMed...
    18. Buckley L et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol, 2017; 69(8): p. 1521-1537. Go to original source... Go to PubMed...
    19. Ferrari SL et al. Childhood fractures are associated with decreased bone mass gain during puberty: an early marker of persistent bone fragility? J Bone Miner Res, 2006; 21(4): p. 501-507. Go to original source... Go to PubMed...
    20. Greendale GA et al. Premenopausal and early postmenopausal trabecular bone score (TBS) and fracture risk: Study of Women's Health Across the Nation (SWAN). Bone, 2020; 140: p. 115543. Go to original source... Go to PubMed...
    21. Kužma M et al. High Serum Fractalkine is Associated with Lower Trabecular Bone Score in Premenopausal Women with Graves' Disease. Horm Metab Res, 2018; 50(8): p. 609-614. Go to original source... Go to PubMed...
    22. Jackuliak P et al. Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. Physiol Res, 2019; 68(Suppl 2): p. S149-s156. Go to original source... Go to PubMed...
    23. Ross AC et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol M et al. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol, 1993; 121(2): p. 217-223.
    24. Piazza G, Campia U, Hurwitz S,et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020; 76: 2060-2072. Go to original source... Go to PubMed...
    25. Sokal A et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int, 2019; 30(1): p. 221-229. Go to original source... Go to PubMed...
    26. Cohen A, Shane E. Evaluation and management of the premenopausal woman with low BMD. Current osteoporosis reports, 2013; 11(4): p. 276-285. Go to original source... Go to PubMed...
    27. Fink HA et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med, 2019; 171(1): p. 37-50. Go to original source... Go to PubMed...
    28. Wotton CJ et al. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. Bone, 2019. 124: p. 69-74. Go to original source... Go to PubMed...
    29. Wood J et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther, 2002; 302(3): p. 1055-1061. Go to original source... Go to PubMed...
    30. Taxel P et al. Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. Journal of the Endocrine Society, 2018; 2(7): p. 574-588. Go to original source... Go to PubMed...
    31. Gnant M et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol, 2011; 12(7): p. 631-641. Go to original source... Go to PubMed...
    32. Hershman DL et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab, 2010; 95(2): p. 559-566. Go to original source... Go to PubMed...
    33. Delmas PD et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol, 1997; 15(3): p. 955-962. Go to original source... Go to PubMed...
    34. Hines SL et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol, 2009; 27(7): p. 1047-1053. Go to original source... Go to PubMed...
    35. Bone HG et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 2008; 93(6): p. 2149-2157. Go to original source... Go to PubMed...
    36. Finkelstein JS et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. Jama, 1998; 280(12): p. 1067-1073. Go to original source... Go to PubMed...
    37. Cohen A et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab, 2013; 98(5): p. 1971-1981. Go to original source... Go to PubMed...
    38. Choe EY et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab, 2012; 30(5): p. 596-601. Go to original source... Go to PubMed...
    39. Langdahl BL et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int, 2009; 20(12): p. 2095-2104. Go to original source... Go to PubMed...
    40. Curtis JR et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum, 2006; 55(3): p. 420-426. Go to original source... Go to PubMed...
    41. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol, 2015; 11(2): p. 98-109. Go to original source... Go to PubMed...
    42. Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. Drug Healthc Patient Saf, 2010; 2: p. 49-59. Go to original source... Go to PubMed...
    43. Van Staa TP et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res, 2000; 15(6): p. 993-1000. Go to original source... Go to PubMed...
    44. Miller KK et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab, 2006; 91(8): p. 2931-2937. Go to original source... Go to PubMed...
    45. Tichá Ľ et al. Porucha kostného metabolizmu pri mentálnej anorexii Čes-slov Pediat., 2016; 71(5-6): p. 287-292.
    46. Sim LA et al. Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses. Int J Eat Disord, 2010; 43(3): p. 218-225. Go to original source... Go to PubMed...
    47. Baqi L et al. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women. Endocr Regul, 2010; 44(2): p. 57-63. Go to original source... Go to PubMed...
    48. Kuzma M, Payer J. (Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures). Cas Lek Cesk, 2010; 149(5): p. 211-216. Go to PubMed...
    49. Kužma M et al. (Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood). Vnitr Lek, 2017; 63(10): p. 658-661. Go to original source... Go to PubMed...
    50. Kužma M et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res, 2014; 24(1): p. 22-28. Go to original source... Go to PubMed...
    51. Kužma M et al. Kvalita kosti u akromegalikov. Vnitřní lékařství, 2017; 63(9): p. 589-592. Go to original source... Go to PubMed...
    52. Kužma M et al. Trabecular Bone Score Change Differs with Regard to 25(OH)D Levels in Patients Treated for Adult-Onset Growth Hormone Deficiency. Endocrine Practice, 2016; 22(8): p. 951-958. Go to original source... Go to PubMed...
    53. Kužma M et al. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol, 2019; 180(3): p. 201-211. Go to original source... Go to PubMed...
    54. World Health, O., Guideline: calcium supplementation in pregnant women. 2013, Geneva: World Health Organization.
    55. Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011; 96(7): p. 1911-1930. Go to original source... Go to PubMed...
    56. Kalkwarf HJ et al. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med, 1997; 337(8): p. 523-528. Go to original source... Go to PubMed...
    57. Scioscia MF et al. Severe Bone Microarchitecture Impairment in Women With Pregnancy and Lactation-Associated Osteoporosis. J Endocr Soc, 2021; 5(5): p. bvab031. Go to original source... Go to PubMed...
    58. O'Sullivan SM et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int, 2006; 17(7): p. 1008-1012. Go to original source... Go to PubMed...
    59. Cerit ET, Cerit M. A case of pregnancy and lactation associated osteoporosis in the third pregnancy; robust response to teriparatide despite delayed administration. Bone reports, 2020; 13: p. 100706-100706. Go to original source... Go to PubMed...
    60. Recker RR et al. Bone gain in young adult women. Jama, 1992; 268(17): p. 2403-2408. Go to original source... Go to PubMed...
    61. Peris P et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol, 2007; 26(6): p. 958-961. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.